Clinical trial
A Pilot Open Label, Multi-dose, Phase 2 Study to Assess the Safety and Efficacy of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)
NCT03946449 is registered in ClinicalTrials.gov with Arrowhead Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Pilot Open Label, Multi-dose, Phase 2 Study to Assess the Safety and Efficacy of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)
- Lead sponsor
- Arrowhead Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 31, 2019
- Completion date
- December 14, 2023
- Enrollment
- 16 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.